Evidence map›Paper›PMID 40330159›Full record

ArticleCase reports in oncology

Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report.

Keisuke Baba, Tomoki Tanie, Yasuo Matsubara, Yoshihiro Hirata, Hiroaki Ikematsu, Narikazu Boku

Abstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Keisuke BabaDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tomoki TanieDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasuo MatsubaraDepartment of Gastroenterology, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoshihiro HirataDepartment of Gastroenterology, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroaki IkematsuDepartment of Gastroenterology, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Malignant ascites due to peritoneal metastasis of gastric cancer is challenging to manage, especially in frail and elderly patients. Traditional treatments like diuretics and paracentesis offer limited relief and can lead to complications such as malnutrition and dehydration. The Denver shunt, a type of peritoneal venous shunt (PVS), can alleviate symptoms but carries risks of severe complications like acute heart failure and disseminated intravascular coagulation (DIC). Assessing patient tolerance before Denver shunt insertion is crucial to prevent life-threatening events. Case Presentation: An 82-year-old woman with advanced gastric cancer developed refractory malignant ascites unresponsive to diuretics and cell-free and concentrated ascites reinfusion therapy (CART). Given her age and frailty, along with the small amount of blood in the ascites, there were concerns about the risks associated with a Denver shunt. An extracorporeal PVS was employed to reinfuse ascites at a controlled rate using an infusion pump. The infusion started at 40 mL/h and was carefully monitored. When the patient experienced paroxysmal supraventricular tachycardia at 60 mL/h, the rate was reduced, and β-blocker therapy was initiated. No signs of heart failure, infusion reactions, or DIC were observed during the 8-day extracorporeal reinfusion. After confirming stable laboratory tests including D-dimer levels which elevated slightly on day 3 and decreased on day 7 without intervention, a Denver shunt was safely inserted without severe complications. Thereafter, patient's ascites was effectively managed, not deteriorating her quality of life, until her passing away 2 months later. Conclusion: This case suggests that extracorporeal PVS, in which controlled reinfusion of ascites for several days can prevent acute complication and monitor potential adverse events, can be a valuable prior treatment before Denver shunt insertion in patients with malignant ascites, especially for frail and elderly patients.

Indexed as

Cell-free and concentrated ascites reinfusion therapyDenver shuntExtracorporeal circulation of ascitesGastric cancerPeritoneal venous shunt

Identifiers

PMID40330159
PMCPMC11867636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.